ストックスクリーナーアプリを入手
7.0999
0.72%
0.1999
前日終値:
$6.90
開ける：
$6.98
24時間の取引高:
21,677
Relative Volume:
0.03
時価総額：
$14.33M
収益：
-
当期純損益:
$-17.10M
株価収益率:
-0.03
EPS:
-236.7281
ネットキャッシュフロー:
$-15.92M
1週間 パフォーマンス:
+2.21%
1か月 パフォーマンス:
+24.78%
6か月 パフォーマンス:
-12.48%
1年 パフォーマンス:
-0.86%
1日の値動き範囲:
$6.91
$7.1606
1週間の範囲:
$6.4401
$7.22
52週間の値動き範囲:
$3.25
$41.80
Quoin Pharmaceuticals Ltd Adr Stock (QNRX) Company Profile
名前
Quoin Pharmaceuticals Ltd Adr
セクター
電話
97299741444
住所
23 HATA'AS STREET, KFAR SABA
Compare QNRX vs VRTX, REGN, MRNA, ARGX, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
QNRX
Quoin Pharmaceuticals Ltd Adr
|
7.1374 | 13.64M | 0 | -17.10M | -15.92M | -236.73 |
VRTX
Vertex Pharmaceuticals Inc
|
523.44 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
810.00 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
180.39 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
976.26 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
193.88 | 43.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Quoin Pharmaceuticals Ltd Adr (QNRX) 最新ニュース
A doctor met a critically ill baby in the ICU, then adopted her - Stock Titan
Tuesday’s insider buys and sells: Quoin Pharma executives lead purchases - Investing.com
Quoin Pharmaceuticals CEO Michael Myers buys $99,991 ADSs - Investing.com
Quoin Pharmaceuticals director Culverwell buys $29,992 in ADSs - Investing.com
Quoin Pharmaceuticals CFO Lawlor buys $49,990 in company stock - Investing.com
Dow Gains 100 Points; Chicago PMI Falls In August - Sahm
Quoin Pharmaceuticals Stock Surges Friday: What's Happening? - Sahm
Why Elastic Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket - Sahm
Quoin Pharmaceuticals raises $30.8M in private placement - Investing.com
Quoin Pharmaceuticals Announces Private Placement Financing of Up to $50.0 Million - Barchart.com
Dow rises 100 points as Chicago PMI misses estimates in August - scanx.trade
Quoin Pharmaceuticals | 10-Q: Q2 2026 Earnings Report - Moomoo
Quoin Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2026 Financial Results - Barchart.com
Quoin Pharmaceuticals to Announce Corporate Update and Second Quarter 2026 Financial Results on Friday, August 14, 2026 - Barchart.com
Cash flow from investing activities of Quoin Pharmaceuticals. Ltd Sponsored ADR – LS:A41BEM - TradingView
Cash flow from financing activities of Quoin Pharmaceuticals. Ltd Sponsored ADR – LS:A41BEM - TradingView
Book value per share of Quoin Pharmaceuticals. Ltd Sponsored ADR – LS:A41BEM - TradingView
Average basic shares outstanding of Quoin Pharmaceuticals. Ltd Sponsored ADR – LSX:A41BEM - TradingView
Insider Traders Lose US$65k As Quoin Pharmaceuticals Drops - Sahm
Price to earnings forward of Quoin Pharmaceuticals. Ltd Sponsored ADR – FWB:2EB0 - TradingView
Price to book forward of Quoin Pharmaceuticals. Ltd Sponsored ADR – FWB:2EB0 - TradingView
Enterprise value to EBIT forward of Quoin Pharmaceuticals. Ltd Sponsored ADR – FWB:2EB0 - TradingView
Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin Syndrome - Sahm
Form PRE 14A Quoin Pharmaceuticals Ltd. For: 6 July By Investing.com - Investing.com India
QNRXQuoin Pharmaceuticals Ltd ADR Volatility & Greeks - Finviz
Quoin Pharmaceuticals. Ltd Sponsored ADR Actuals & Estimates (NASDAQ:QNRX) - TradingView
Why Leifras Shares Are Trading Higher By Around 23%; Here Are 20 Stocks Moving Premarket - Benzinga
Quoin Pharmaceuticals Receives FDA Conditional Approval of QYLEKI™ as the Proposed Brand Name for QRX003 for Netherton Syndrome - Sahm
These stocks that are showing activity before the opening bell on Wednesday. - ChartMill
Trending Stocks Today | Quoin Pharmaceuticals Shoots up 41.6% Post-Market - Moomoo
Quoin Pharmaceuticals establishes Japan subsidiary for QRX003 - Investing.com
Quoin Pharmaceuticals Announces Positive Clinical Update from Ongoing Pediatric Netherton Syndrome Compassionate Use Program - Sahm
Quoin Pharmaceuticals Announces Japan's MHLW Grants Orphan Drug Designation for QRX003 in Netherton Syndrome - Sahm
Quoin Pharmaceuticals stock rises on rare disease IND filing By Investing.com - Investing.com South Africa
Quoin Pharmaceuticals stock rises on rare disease IND filing - Investing.com
Number of shareholders of Quoin Pharmaceuticals. Ltd Sponsored ADR – FWB:2EB0 - TradingView
Quoin Pharmaceuticals (QNRX) Earnings Date and Reports 2026 - marketbeat.com
Quoin Pharmaceuticals initiated with a Buy at Lucid Capital - TipRanks
Quoin Pharmaceuticals to Announce Corporate Update and First Quarter 2026 Financial Results on Thursday, May 7, 2026 - Sahm
Quoin Pharmaceuticals DRC News Today (QNRX) - Investing.com
Quoin Pharmaceuticals provides regulatory update on QRX009 topical rapamycin - TipRanks
Unusual VolumeStock ScreenerNews - Finviz
CORRECTION -- Quoin Pharmaceuticals Provides Clinical and Regulatory Update for QRX009 Topical Rapamycin Development Programs - Sahm
Quoin Pharmaceuticals price target raised to $35 from $25 at Alliance Global - TipRanks
Quoin Pharmaceuticals (NASDAQ: QNRX) advances NS drug but warns on cash - Stock Titan
Quoin Pharmaceuticals provides update following QRX003 Type C meeting with FDA - TipRanks
Quoin Pharmaceuticals to Announce Corporate Update and Fourth Quarter and Full-Year 2025 Financial Results on Thursday, March 26, 2026 - ChartMill
Quoin Pharmaceuticals Announces FDA Grants Fast Track Designation for QRX003 for the Treatment of Netherton Syndrome - Sahm
Maxim Group Sticks to Its Buy Rating for Quoin Pharmaceuticals (QNRX) - The Globe and Mail
Form 13G Quoin Pharmaceuticals For: 15 December - Investing.com
US Stock Market today: Nasdaq, S&P 500 open lower amid elevated tech valuation concerns, Dow Jones up 0.17% - Livemint
Quoin Pharmaceuticals Ltd Adr (QNRX) 財務データ
収益
当期純利益
現金流量
EPS
Quoin Pharmaceuticals Ltd Adr (QNRX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Myers Michael | Chief Executive Officer |
Aug 31 '26 |
Buy |
4.88 |
20,490 |
99,991 |
37,713 |
| Lawlor Sally Bridget | Chief Financial Officer |
Aug 31 '26 |
Buy |
4.88 |
10,244 |
49,991 |
10,684 |
| Culverwell Anthony James | Director |
Aug 31 '26 |
Buy |
4.88 |
6,146 |
29,992 |
40,364 |
| LANGER DENNIS | Director |
Oct 14 '25 |
Buy |
8.49 |
15,152 |
128,640 |
15,153 |
0.27%
0.91%
大文字化:
|
ボリューム (24 時間):